Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oligomerix Inc.

www.oligomerix.com

Latest From Oligomerix Inc.

Finance Watch: Government Grants Galore And Other New Funding Sources

While Forbion's new €360m venture capital fund and other investors have emerged to fund private and public companies, BARDA and other US agencies have been active supporters of biopharma firms in recent weeks. Also, KSQ grabs $80m in VC cash and VelosBios brings in $50m.

Financing StartUps and SMEs

Investors Find Opportunity In Tau-Targeting Biopharmas

Tau-targeting Alzheimer's candidates, though historically rejected in favor of amyloid-beta targeting ones, have gained increasing interest from investors and larger pharma companies.

BioPharmaceutical Deals

Oligomerix Inc.

Oligomerix Inc. is increasingly confident that small aggregates of the protein tau are a key culprit in the progression of Alzheimer’s disease. It aims to inhibit tau oligomer formation or self-association, the initial steps in aggregation of the protein, and thereby interrupt the disease process at a relatively early juncture.

BioPharmaceutical

Start-Up Previews, July-August 2013

This Month's Profile Groups: Ocular Gene Therapy Sees The Light, features profiles of Avalanche Biotechnologies, Eyevensys, GenSight Biologics, and Hemera Biosciences; Smart Orthopedic Implants, feature profiles of OrthoData and Ortho-tag. Plus these Start-Ups Across Health Care: Colibri Heart Valve, Complix, Helmedix, Mapi Pharma, Mendor, Oligomerix, QuantuMDx, Silicon BioDevices, and Vigilant Biosciences.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Oligomerix Inc.
  • Senior Management
  • James Moe, PhD, Pres. & CEO
    David Davidowitz, PhD, CSO
    Jack Pasini, Chief Commercial Officer
  • Contact Info
  • Oligomerix Inc.
    Phone: (212) 568-0365
    3960 Broadway
    Ste. 340D
    New York, NY 10032
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register